394 related articles for article (PubMed ID: 25786618)
1. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
Wan C; Allen TM; Cullis PR
Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
[TBL] [Abstract][Full Text] [Related]
2. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
3. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
5. On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
Kulkarni JA; Darjuan MM; Mercer JE; Chen S; van der Meel R; Thewalt JL; Tam YYC; Cullis PR
ACS Nano; 2018 May; 12(5):4787-4795. PubMed ID: 29614232
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
7. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
Cheng X; Lee RJ
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
[TBL] [Abstract][Full Text] [Related]
8. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
9. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
[TBL] [Abstract][Full Text] [Related]
10. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
11. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
Kulkarni JA; Cullis PR; van der Meel R
Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
[TBL] [Abstract][Full Text] [Related]
12. Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR; Hope MJ
Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
[TBL] [Abstract][Full Text] [Related]
13. Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.
Wang X; Yu B; Wu Y; Lee RJ; Lee LJ
Anticancer Res; 2011 May; 31(5):1619-26. PubMed ID: 21617218
[TBL] [Abstract][Full Text] [Related]
14. Determination of the interior pH of lipid nanoparticles using a pH-sensitive fluorescent dye-based DNA probe.
Zhao B; Kamanzi A; Zhang Y; Chan KYT; Robertson M; Leslie S; Cullis PR
Biosens Bioelectron; 2024 May; 251():116065. PubMed ID: 38330772
[TBL] [Abstract][Full Text] [Related]
15. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
16. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells.
Uemura Y; Naoi T; Kanai Y; Kobayashi K
Pharm Dev Technol; 2019 Mar; 24(3):263-268. PubMed ID: 29688101
[TBL] [Abstract][Full Text] [Related]
17. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
19. Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids.
Ehexige E; Ganbold T; Yu X; Han S; Baigude H
Molecules; 2019 Sep; 24(18):. PubMed ID: 31546908
[TBL] [Abstract][Full Text] [Related]
20. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]